{"filing":{"accession_number":"0001213900-26-086007","cik":"0001875091","ticker":"NRSNW","company_name":"NeuroSense Therapeutics Ltd.","form":"6-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ea0300915-6k_neuro.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026086007/ea0300915-6k_neuro.htm"},"events":[{"id":24538,"run_id":22245,"accession_number":"0001213900-26-086007","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"NeuroSense announced completion of the Pre-NDS process with Health Canada and a December 2026 filing target for PrimeC's New Drug Submission in ALS. This is a material regulatory milestone—successful alignment with a foreign health authority on submission content and structure—that advances the company's lead therapeutic candidate toward potential commercialization. While not a discrete event type like M\u0026A or exec change, this operational/regulatory progress is material to investors assessing the company's clinical development trajectory and near-term catalysts.","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":[{"id":25132,"accession_number":"0001213900-26-086007","item_number":"EX-99.1","item_title":"ea030091501ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"NeuroSense announced completion of the Pre-NDS process with Health Canada and a December 2026 filing target for PrimeC's New Drug Submission in ALS. This is a material regulatory milestone—successful alignment with a foreign health authority on submission content and structure—that advances the company's lead therapeutic candidate toward potential commercialization. While not a discrete event type like M\u0026A or exec change, this operational/regulatory progress is material to investors assessing the company's clinical development trajectory and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:06:53.752619+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25132,"accession_number":"0001213900-26-086007","item_number":"EX-99.1","item_title":"ea030091501ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"NeuroSense announced completion of the Pre-NDS process with Health Canada and a December 2026 filing target for PrimeC's New Drug Submission in ALS. This is a material regulatory milestone—successful alignment with a foreign health authority on submission content and structure—that advances the company's lead therapeutic candidate toward potential commercialization. While not a discrete event type like M\u0026A or exec change, this operational/regulatory progress is material to investors assessing the company's clinical development trajectory and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:06:53.752619+00:00","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-08-06"}]}